In this long-term follow up of the ABSORB IV trial, the five-year rate of target lesion failure was significantly higher with the everolimus-eluting bioabsorbable scaffold compared with its metallic counterpart, despite strict adherence to recommended implantation techniques.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content